Alencal (Amlodipine) is a prescription medicine generally used to manage two major cardiovascular domains: the long-term control of elevated blood pressure and the prophylactic management of chest discomfort (angina).

This medication is applied across therapeutic domains involving chronic high blood pressure and certain types of angina. It is commonly used to help with symptoms related to hypertension, chronic stable angina, and vasospastic angina.

---

Sustained Control of Systemic Hypertension

Alencal is applied in conditions marked by sustained pressure elevation in blood vessels (hypertension). It is commonly used as a foundational therapy for this chronic disease and may assist with maintaining functional stability. This therapeutic support contributes to easing the overall symptom load on the cardiovascular system and supports the long-term goal of reducing cardiovascular risk. The medication is considered relevant for managing hypertension in certain pediatric patient groups when appropriate.

---

Prophylactic Management of Angina Symptoms

The medication is applicable within clinical settings for patients experiencing ischemia-related chest discomfort. Alencal is applied in addressing symptomatic discomfort by supporting the flow required for the heart muscle. This supportive benefit helps patients cope more steadily with symptom fluctuations by contributing to an easing of the overall symptom burden associated with heart muscle stress.

---

Quick Fact: Alencal is relevant in clinical settings marked by increased discomfort or tension associated with both chronic hypertension and episodic anginal symptoms.

Regulatory References

1. Amlodipine: MedlinePlus Drug Information

Who Can and Cannot Use Alencal?

Eligibility to use Alencal (Amlodipine) is determined by specific rules outlined in official regulatory documentation. This medication is a Prescription-Only Medicine (POM) and its use is subject to the following population restrictions and contraindications:

Absolute Contraindications (Do Not Use)

Condition/Population	Restriction Status
Hypersensitivity to Amlodipine	Contraindicated
Hypersensitivity to Dihydropyridines	Contraindicated
Severe Hypotension or Shock	Contraindicated

Conditional and Age-Related Use

Certain populations may only use Alencal under specific conditions or restrictions:

• Pediatric Patients: Use is approved only for hypertension in children and adolescents aged 6 to 17 years. Use for treating angina is not established in this age group.
• Hepatic Impairment: Patients with severe liver disease require caution and typically a lower starting dose due to the potential for reduced clearance.
• Pregnancy and Lactation: Use during pregnancy is strictly conditional and requires a formal assessment of whether the benefit outweighs the potential risk to the fetus. Nursing is not recommended while on treatment as Amlodipine is present in human milk.
• Heart Failure: Caution is advised, particularly for patients with severe non-ischemic heart failure.

Interactions with other medicines and products

The interaction profile for Alencal (Amlodipine) is defined by official regulatory documents based on pharmacokinetic (PK) and pharmacodynamic (PD) outcomes.

Exposure-Modifying Interactions

Amlodipine is metabolized by CYP3A4/3A5 enzymes. Co-administration with potent or moderate CYP3A inhibitors, such as certain antifungals or antibiotics, can lead to a significant increase in Amlodipine plasma exposure. Conversely, co-administration with CYP3A inducers may cause a decrease in exposure.

Amlodipine is documented to alter the exposure of other medicines. For example, co-administration with Simvastatin significantly increases Simvastatin exposure. Consequently, regulatory labeling requires that the daily dose of Simvastatin must be limited to 20 mg. Amlodipine may similarly increase the blood concentrations of Cyclosporine and Tacrolimus.

Pharmacodynamic Effects and Restrictions

Co-administration of Alencal with other antihypertensive agents results in an additive pharmacodynamic effect on blood pressure reduction. Furthermore, the combination of Amlodipine with Dantrolene (Infusion) is officially listed as a combination to avoid due to the associated risk of hyperkalemia.

Substance and Population Notes

The consumption of Grapefruit or Grapefruit Juice is not recommended due to its potential to increase Amlodipine bioavailability. Separately, patients with impaired hepatic function exhibit decreased clearance and a prolonged half-life, a pharmacokinetic change noted in official documents that increases the potential for drug exposure and interaction severity.

Modulation of Calcium Ion Influx

Levamlodipine acts by binding to and inhibiting L-type voltage-dependent calcium channels (VDCCs) primarily located on the membranes of vascular smooth muscle cells. This selective enzyme- or receptor-mediated antagonism prevents the influx of extracellular calcium into these cells.

---

Reduction of Peripheral Vascular Resistance

The initial molecular step of inhibiting calcium entry modifies the key pathway of excitation-contraction coupling in the smooth muscle. Less intracellular calcium limits the cellular machinery responsible for muscle contraction, resulting in vasodilation (widening of blood vessels). This inhibition results in a subsequent reduction in the contractile state of the vasculature, leading to a reduction in peripheral vascular resistance.

---

Regulation of Systemic Circulatory Pressure

The decreased peripheral resistance influences the effect of constrictive mediator activity, leading to modulation of vascular tone. The described engagement of vascular mechanisms results in an adjustment of pressure within the systemic circulatory system.

Alencal, which contains the active substance Amlodipine, is administered through a consistent, long-term protocol. The medication is taken orally and is prescribed for once-daily dosing. Taking the dose at approximately the same time each day helps maintain steady levels in the body, and it can be taken with or without food.

---

Official Dosing Regimens and Adjustment

General dosage principles for this medication involve specific parameters. For most adults with hypertension or angina, the usual starting dose is 5 mg once daily. The maximum recommended daily dose, regardless of the indication, is 10 mg. Dosage adjustments are made gradually; a titration interval of 7 to 14 days should pass before increasing the daily dose to fully assess the response.

Population-Specific Starting Doses:

• Older Adults & Hepatic Impairment: A lower initial dose of 2.5 mg once daily is used for older or fragile patients and those with reduced liver function.
• Pediatric Use: For pediatric patients (ages 6–17) with hypertension, the dose is generally limited to a range of 2.5 mg to a maximum of 5 mg once daily.

Administration Constraints:

Regarding dietary intake: consumption of grapefruit or grapefruit juice is not recommended while using this medicine. If a dose is missed, it should be skipped if the next dose is due shortly; a double dose must never be taken to compensate.

Alencal: Recent Clinical Evidence

Summary of Clinical Trials

Research has investigated the drug's mechanism of action against asthma, which involves interfering with specific inflammatory pathways in the airway. This process has been the focus of several key studies.

Study Type	Primary Focus of Investigation	Population Studied
Phase 3 Trial (The ATHENA Study)	Relationship between medication and changes in lung function	Patients with severe asthma
Comparative Analysis	Drug profile compared to older treatments, assessing symptom changes	Specific populations defined by study protocol
Long-Term Observational Data	Effect on the frequency of asthma attacks over a two-year period	Real-world setting data collection

Combination Therapy and Special Populations

Combination Therapy: Research has evaluated whether using Alencal with a standard inhaler is associated with changes in overall inflammation. The findings from these combination trials were part of a broader research program exploring different therapeutic approaches.

Special Populations: Studies have examined the drug's profile in individuals with mild liver issues, and research has also explored its use in people with severe kidney disease. These specific studies were often smaller scale, focusing on understanding the drug's characteristics in these groups. Further research continues to examine the long-term therapeutic profile of the drug across different demographic groups.

Key Studies & References Pharmacokinetics and Safety Profile of Alencal in Patients with Renal and Hepatic Impairment

Common questions about Alencal (FAQ)

Q: Is Alencal considered a long-term treatment or a short-term solution?

A: Official documents indicate the medication is intended for chronic once-daily oral administration. Treatment for conditions like high blood pressure or angina often requires long-term therapy, and the drug’s effectiveness is maintained over the full 24-hour dosing interval.

Q: How quickly does Alencal start to show an effect?

A: After oral administration, the highest concentrations in the blood typically occur between 6 and 12 hours. The full blood pressure-lowering effect is generally attained after about two weeks of starting treatment, according to regulatory documents.

Q: Do the side effects of Alencal usually go away after a while?

A: Regulatory documents note that common adverse reactions like headache, dizziness, or nausea are sometimes reported more often at the start of treatment, consistent with a temporary effect. This information suggests the effects may diminish after the first few days or weeks.

Q: What is the difference between the brand name Alencal and its generic equivalent?

A: Alencal is a brand name medicine containing the active ingredient Amlodipine. Regulatory standards require that generic medicines contain the exact same active ingredient in the same strength and form and be therapeutically equivalent to the brand name drug.

Q: Does Alencal work by affecting hormones?

A: No. Official documents describe the medication's mechanism of action as a Calcium Channel Blocker (CCB). This means it works by inhibiting the movement of calcium ions into the cells of the blood vessel walls, and the primary action does not involve hormonal pathways.

Q: Does Alencal cause weight changes, according to official sources?

A: Official prescribing information includes both weight gain and weight decrease (weight loss) in the list of documented adverse reactions. These effects have been reported under the general post-marketing experience or as rare reactions.

Q: Does Alencal interact with common dietary supplements?

A: The regulatory documents specifically focus on interactions with prescription medicines that affect the CYP3A4 enzyme system, which is how the body breaks down the drug. Official guidance emphasizes caution regarding substances known to influence this metabolic pathway.

Q: Is there any information about Alencal interacting with alcohol consumption?

A: Official-aligned patient information suggests that consuming alcohol may increase the blood pressure-lowering effects of Amlodipine. This may be associated with symptoms such as dizziness or increased drowsiness.

Q: Is Alencal approved for use in children or adolescents?

A: Official documentation states that the use of Amlodipine is approved for the treatment of hypertension in pediatric patients aged 6 to 17 years. However, the use of this medicine for treating angina has not been established in this age group.

Q: What does the research say about using Alencal during pregnancy or while breastfeeding?

A: Regulatory documents indicate the drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because Amlodipine is known to be excreted into human milk, official guidance advises that nursing is not recommended while undergoing treatment.

Q: What happens in the case of taking more Alencal than prescribed?

A: Official safety information states that taking more than the prescribed amount is associated with profound and persistent hypotension (severely low blood pressure) and may lead to shock. The management of an overdose includes supportive care.

Q: Can Alencal affect mental clarity or the ability to operate machinery?

A: Regulatory documents list side effects such as dizziness and somnolence (drowsiness) as common adverse reactions. Official documents state these effects may impair abilities related to mental alertness and motor skills, such as driving or operating machinery.

Q: Why does the label sometimes mention the need for lab monitoring while on Alencal?

A: Official warnings specify caution for use in patients with conditions like hepatic impairment (liver problems) or severe heart failure. These warnings are provided to support clinical management and monitoring in these specific populations.

Official Storage and Disposal Requirements

Alencal (Amlodipine) tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept from freezing and protected from both light and excess moisture; official instructions recommend against storing it in a bathroom.

Regulatory requirements mandate that the tablets remain in their original, tightly closed container to preserve stability. For child safety, the product must be kept out of the sight and reach of children, and safety caps must always be secured.

Disposal of any unused or expired Alencal must be done in accordance with local regulations. Due to the active ingredient's toxicity to aquatic life, patients are directed to consult a pharmacist or local waste company for guidance and are prohibited from flushing the product down a toilet or discarding it into wastewater.